GSK Overhauls Pipeline: Terminates $100M STING ADC XMT-2056 and Pauses mRNA Avian Flu Vaccine

Apr 30, 2026 13:33 CST Updated 13:33

GSK

Pharmaceutical R&D Manufacturer

On April 29, 2026, the multinational pharmaceutical company GSK disclosed three major adjustments to its core pipeline in the first quarter financial report of 2026—Termination of the STING Agonist ADC Project XMT-2056, Nearly 4 Years of Collaboration with Mersana Therapeutics, and Suspension of mRNA Avian Influenza Vaccine Development, meanwhileTermination of a TLR8 Agonist Project for Chronic Hepatitis B. This giant, deeply invested in the ADC and infectious disease vaccine fields, has decisively kicked off the Q1 earnings season for multinational pharmaceutical companies with a bold pipeline "decluttering."

$100 Million Bet on STING ADC Ends in Failure

The XMT-2056 project, which GSK has now terminated, was a core asset in its collaboration with Mersana and also one of the landmark projects in the STING ADC field.

Looking back at 2022, GSK entered into a collaboration agreement with Mersana to secure the exclusive rights for the development and commercialization of XMT-2056, paying an upfront fee of $100 million. Additionally, milestone payments of up to $1.36 billion were agreed upon. At that time, the industry held high hopes for this product: developed on Mersana's proprietary immunosynthen platform, it is a STING agonist ADC targeting HER2, designed to activate the innate immune system through the STING signaling pathway, enabling precise targeting of HER2-expressing solid tumors. It was once considered a potential breakthrough candidate for overcoming resistance in HER2-targeted therapies and expanding indications.

But the clinical path of this star product has been thorny from the very beginning. In 2023, XMT-2056 was reported to be highly associated with severe bleeding events in a Phase I clinical trial involving platinum-resistant ovarian cancer patients, including five fatal cases. The U.S. FDA promptly issued a partial clinical hold on the project, casting a thick shadow over its future.

Even so, GSK still held expectations for the project afterward — in 2025, GSK paid Mersana a milestone payment of $15 million and did not directly terminate the collaboration. At that time, Mersana was in the process of being acquired by Day One Therapeutics, and the industry was still watching to see if GSK would take over and advance this product.

In this Q1 earnings report, GSK officially removed XMT-2056 from its Phase I clinical pipeline, bringing an end to the nearly four-year collaboration that accumulated over $100 million in investment. According to Fierce Biotech, this decision was GSK's final call after a comprehensive evaluation of the existing clinical data.

Notably, the termination of the collaboration with Mersana does not imply that GSK is abandoning its presence in the ADC sector. On the contrary, GSK is accelerating the advancement of its proprietary ADC pipeline: Blenrep, its ADC product for multiple myeloma, has already been successfully commercialized. In early April this year, GSK announced plans to initiate five late-stage clinical trials within the "coming months" for mocertatug rezetecan, a B7-H4-targeted ADC acquired from Hansoh Pharma. While cutting high-risk early-stage collaborative projects, GSK is doubling down on late-stage core assets with higher certainty, showcasing a clear strategic focus on its ADC portfolio.

mRNA Pipeline Priority Major Adjustment: Avian Influenza Vaccine Suspended, Full Bet on Seasonal Flu

In addition to the termination of the ADC project, GSK also announced significant adjustments to its mRNA vaccine pipeline: the suspension of the development of the mRNA avian influenza vaccine project GSK5536522.

For the core reason of the suspension, GSK explicitly stated that it aims to prioritize the allocation of R&D resources and production capacity to the seasonal influenza mRNA vaccine GSK4382276, which is currently in Phase II clinical trials. According to disclosures, GSK is currently focusing on building its own mRNA technology platform and refining large-scale production processes. Once the platform and production system are fully operational, the company will reassess the development timeline for the avian influenza vaccine project.

The industry was not surprised by this adjustment. In fact, GSK has a mature layout in the field of avian influenza prevention and control — it already has a monovalent avian influenza vaccine approved by the FDA, mainly used for national stockpiling in the event of a pandemic risk, and the foundation for emergency prevention and control remains unshaken. Seasonal flu vaccines, on the other hand, are a core product in the global vaccine market, with far greater commercial potential and certainty compared to avian influenza vaccines with emergency attributes. For GSK, which entered the mRNA space relatively late, it is undoubtedly a more pragmatic choice to first complete the clinical validation, production capacity implementation, and commercial closed-loop of its mRNA platform through seasonal flu vaccines.

HBV Pipeline Simultaneously Streamlined, Fully Striving for "Functional Cure"

In this pipeline adjustment, GSK also simultaneously terminated the development of GSK5251738, a TLR8 agonist project for chronic hepatitis B.

Interestingly, in the same week the project was terminated, GSK's core product in the hepatitis B pipeline — the antisense oligonucleotide drug bepirovirsen — had just been granted Priority Review by the FDA, targeting "functional cure" for chronic hepatitis B, with a PDUFA date set for January 2027. While cutting early-stage pipelines, GSK is concentrating resources to push for the launch of its key product, following a strategic logic in the hepatitis B field that mirrors its approach in the ADC and mRNA sectors.

Industry Watch: Big Pharma's Pipeline Pruning as the Industry's Bellwether

GSK's concentrated pipeline adjustment is by no means an isolated case, but rather a microcosm of the current global biopharmaceutical industry.

In recent years, multinational pharmaceutical companies have long abandoned the previous "wide-net, pipeline-expansion" extensive layout, and have fully entered a phase of cost reduction, efficiency enhancement, and focus on core sectors. Even projects that required significant early investment will be decisively terminated if clinical safety risks emerge, data underperforms expectations, or alignment with the company’s core strategy weakens. Resources continue to be concentrated on late-stage pipelines with higher certainty and greater commercial potential.

The termination of XMT-2056 has once again sounded the alarm for the STING赛道. As a popular target in the field of tumor immunology, the challenge of drugability for STING has always loomed over the industry — the toxicity from systemic administration and insufficient efficacy have been difficult obstacles with no breakthrough progress for many years. The industry had hoped that the targeted delivery capability of ADCs would solve the issue of systemic toxicity with STING agonists, but the severe bleeding events and ultimate failure of XMT-2056 have proven that this path still faces significant clinical challenges.

For GSK, this major pipeline reshuffle is not a strategic contraction but a precise focus. Going forward, the success of its B7-H4 ADC, introduced from Hansoh, in advancing to later-stage clinical trials, whether bepirovirsen can successfully secure an indication for functional cure of hepatitis B, and whether its mRNA seasonal flu vaccine can break through in the fiercely competitive track, will all be crucial in determining its future standing in the industry. Meanwhile, the entire biopharmaceutical sector is gaining clarity on the true prospects and future direction of these tracks through the continuous pipeline decisions made by multinational pharmaceutical companies.

Reference Source:https://www.fiercebiotech.com/biotech/gsk-walks-away-100m-bet-mersana-sting-adc-pauses-mrna-bird-flu-shot

Scan the WeChat QR code, add the editor of the Biologics Circle, and those who meet the requirements can join.

Biological Products WeChat Group!

Please indicate: Name + Research Direction!

Edition

Authority

Sound

Ming

All reproduced articles in this official account are intended to convey more information, with the source and author clearly indicated. Media or individuals who do not wish to be reprinted can contact us at cbplib@163.com, and we will delete the content immediately. All articles represent the views of the author and not this site.